| Catalog Number |
PR903565833 |
| CAS |
903565-83-3 |
| Structure |  |
| Description |
Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2. |
| Synonyms |
apleway |
| IUPAC Name |
(3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol |
| Molecular Weight |
386.4 |
| Molecular Formula |
C22H26O6 |
| InChI |
VWVKUNOPTJGDOB-BDHVOXNPSA-N |
| InChI Key |
InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1 |
| Drug Categories |
Benzene Derivatives; Blood Glucose Lowering Agents; Carbohydrates; Glycosides; Sodium-Glucose Transporter 2 Inhibitors |
| Drug Interactions |
Acarbose-The risk or severity of hypoglycemia can be increased when Acarbose is combined with Tofogliflozin.
Acebutolol-The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acebutolol.
Acetazolamide-The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acetazolamide.
Acetohexamide-The risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Tofogliflozin.
Acetyl sulfisoxazole-The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Acetyl sulfisoxazole. |
| Isomeric SMILES |
CCC1=CC=C(C=C1)CC2=CC3=C(CO[C@@]34[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C=C2 |
| Type |
Small Molecule |
| Therapeutic Category |
Antidiabetics |
It should be noted that our service is only used for research, not for clinical use.
